{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:38:01Z","timestamp":1794512281380,"version":"4.9.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016206","name":"Clinical and Translational Science Institute, University of California, Los Angeles","doi-asserted-by":"publisher","award":["UL1TR001881"],"award-info":[{"award-number":["UL1TR001881"]}],"id":[{"id":"10.13039\/100016206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ijrobp.2024.12.018","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T17:14:41Z","timestamp":1735838081000},"page":"93-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pelvic Regional Control With 25 Gy in 5 Fractions in Stereotactic Radiation Therapy for High-Risk Prostate Cancer: Pooled Prospective Outcomes From the SHARP Consortium"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6011-9319","authenticated-orcid":false,"given":"Vedang","family":"Murthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indranil","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyamvada","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gargee","family":"Mulye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Arunsingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Loblaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.12.018_bib0001","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0002","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0003","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0004","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0005","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.027","article-title":"5-year outcomes from PACE B: an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) vs. conventionally fractionated or moderately hypo fractionated external beam radiotherapy for localized prostate cancer","volume":"117","author":"van As","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0006","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.radonc.2003.12.006","article-title":"Sphincter preservation following preoperative radiotherapy for rectal cancer: Report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy","volume":"72","author":"Bujko","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0007","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ijrobp.2023.02.054","article-title":"A randomized feasibility trial of stereotactic prostate radiation therapy with or without elective nodal irradiation in high-risk localized prostate cancer (SPORT Trial)","volume":"117","author":"Houlihan","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0008","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2022.05.050","article-title":"Acute and late adverse effects of prostate-only or pelvic stereotactic radiation therapy in prostate cancer: A comparative study","volume":"114","author":"Murthy","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0009","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.clon.2019.09.046","article-title":"A phase I\/II study of stereotactic hypofractionated once-weekly radiation therapy (SHORT) for prostate cancer","volume":"32","author":"Mallick","year":"2020","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2021.08.017","article-title":"Elective nodal ultra hypofractionated radiation for prostate cancer: safety and efficacy from four prospective clinical trials","volume":"163","author":"Glicksman","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0011","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.ijrobp.2023.09.053","article-title":"Safety of ultrahypofractionated pelvic nodal irradiation in the definitive management of prostate cancer: systematic review and meta-analysis","volume":"118","author":"Mohamad","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0012","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.adro.2018.12.001","article-title":"Early tolerance outcomes of stereotactic hypofractionated accelerated radiation therapy concomitant with pelvic node irradiation in high-risk prostate cancer","volume":"4","author":"Pinitpatcharalert","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0013","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ijrobp.2021.01.016","article-title":"Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) consortium: analysis of 344 prospectively treated patients","volume":"110","author":"van Dams","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0014","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.08.002","article-title":"RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer","volume":"74","author":"Lawton","year":"2009","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0015","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijrobp.2020.08.034","article-title":"NRG Oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer","volume":"109","author":"Hall","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0017","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ijrobp.2007.03.046","article-title":"Moderately low alpha\/beta ratio for rectal cancer may best explain the outcome of three fractionation schedules of preoperative radiotherapy","volume":"69","author":"Suwinski","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.12.018_bib0018","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijrobp.2018.10.003","article-title":"Toxicity and patient-reported outcomes of a phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL)","volume":"103","author":"Dearnaley","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624037738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624037738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T12:26:44Z","timestamp":1744633604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624037738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0360301624037738"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.12.018","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pelvic Regional Control With 25 Gy in 5 Fractions in Stereotactic Radiation Therapy for High-Risk Prostate Cancer: Pooled Prospective Outcomes From the SHARP Consortium","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}